Albireo to receive more than $55 million in nondilutive cash payments
Albireo Pharma announced that Japan’s MHLW has approved the new drug application for elobixibat for treatment of chronic constipation in Japan. Elobixibat is a first-in-class, once-daily, orally available IBAT inhibitor targeted to improve secretion and motility in the large bowel. January 19, 2018